Product nameNicotinic acid (Niacin), antidyslipidemic agent
- vitamin B3
Biological descriptionAntidyslipidemic. Increases high-density- and lowers low-density lipoproteins. Putative ligand for the HM74A receptor.
Chemical namePyridine-3-carboxylic acid
Storage instructionsStore at Room Temperature. The product can be stored for up to 12 months.
Solubility overviewSoluble in water to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120145 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
ab64308 staining ApoA1 in HepG1 cells treated with nicotinic acid (ab120145), by ICC/IF. Decrease in ApoA1 expression correlates with increased concentration of nicotinic acid, as described in literature.
The cells were incubated at 37°C for 72h in media containing different concentrations of ab120145 (nicotinic acid) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab64308 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
This product has been referenced in:
- Soudijn W et al. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27:417-33 (2007). Read more (PubMed: 17238156) »
- Offermanns S The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27:384-90 (2006). Read more (PubMed: 16766048) »
- Carlson LA Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:94-114 (2005). Read more (PubMed: 16018787) »